1. Hung CH, Chiu YC, Chen CH, Hu TH. MicroRNAs in hepatocellular crcinoma: carcinogenesis, progression, and therapeutic target. Biomed Res Int 2014; 2014:486–407.
2. Ursino S, Greco C, Cartei F, Colosimo C, Stefanelli A, Cacopardo B, et al. Radiotherapy and hepatocellular carcinoma: update and review of the literature. Eur Rev Med Pharmacol Sci 2012; 16:1599–1604.
3. Wang S, Bian C, Yang Z, Bo Y, Li J, Zeng L, et al. miR-145 inhibits breast cancer cell growth through RTKN. Int J Oncol 2009; 34:1461–1466.
4. Ostenfeld MS, Bramsen JB, Lamy P, Villadsen SB, Fristrup N, Sørensen KD, et al. miR-145 induces caspase-dependent and-independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. Oncogene 2010; 29:1073–1084.
5. Salim H, Akbar NS, Zong D, Vaculova AH, Lewensohn R, Moshfegh A, et al. miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence. Br J Cancer 2012; 107:1361–1373.
6. Chen G, Zhu W, Shi D, Lv L, Zhang C, Liu P, et al. MicroRNA-181a sensitizes human malignant glioma U87MG cells to radiation by targeting Bcl-2. Oncol Rep 2010; 23:997–1003.
7. Chun-Zhi Z, Lei H, An-Ling Z, Yan-Chao F, Xiao Y, Guang-Xiu W, et al. MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer 2010; 10:367.
8. Shen G, Lin Y, Yang X, Zhang J, Xu Z, Jia H. MicroRNA-26b inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting USP9X. BMC Cancer 2014; 14:393.
9. Mosch B, Pietzsch D, Pietzsch J. Irradiation affects cellular properties and Eph receptor expression in human melanoma cells. Cell Adh Migr 2012; 6, 113–125.
10. Fokas E, Kamlah F, Hänze J, Engenhart-Cabillic R, Rose F, An HX. EphA2 blockade enhances the anti-endothelial effect of radiation and inhibits irradiated tumor cell-induced migration of endothelial cells. Thorac Cancer 2010; 1:153–162.
11. Wu N, Zhao X, Liu M, Liu H, Yao W, Zhang Y, et al. Role of microRNA-26b in glioma development and its mediated regulation on EphA2. PLoS One 2011; 6:16264.
12. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, et al. MicroRNA Expression, Survival, and Response to Interferon in Liver Cancer. N Engl J Med 2009; 361:1437–1447.
13. Verghese ET, Drury R, Green CA, Holliday DL, Lu X, Nash C, et al. MiR-26b is down-regulated in carcinoma-associated ﬁbroblasts from ER-positive breast cancers leading to enhanced cell migration and invasion. J Pathol 2013; 231:388–399.
14. Liu HG, Chen C, Yang H, Pan YF, Zhang XH. Cancer stem cell subsets and their relationships. J Transl Med 2011; 9:50.
15. Zhao N, Wang R, Zhou L, Zhu Y, Gong J, Zhuang SM. MicroRNA-26b suppresses the NF-κB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3. Mol Cancer 2014; 13:35.
16. Annamalai B, Liu XG, Gopal U, Isaacs JS. Hsp90 is an essential regulator of epha2 receptor stability and signaling: implications for cancer cell migration and metastasis. Mol Cancer Res 2009; 7:1021–1032.